JP2014516027A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516027A5
JP2014516027A5 JP2014509823A JP2014509823A JP2014516027A5 JP 2014516027 A5 JP2014516027 A5 JP 2014516027A5 JP 2014509823 A JP2014509823 A JP 2014509823A JP 2014509823 A JP2014509823 A JP 2014509823A JP 2014516027 A5 JP2014516027 A5 JP 2014516027A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
modification
inhibitor
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014509823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516027A (ja
JP6049700B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/051018 external-priority patent/WO2012153135A1/en
Publication of JP2014516027A publication Critical patent/JP2014516027A/ja
Publication of JP2014516027A5 publication Critical patent/JP2014516027A5/ja
Application granted granted Critical
Publication of JP6049700B2 publication Critical patent/JP6049700B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014509823A 2011-05-09 2012-05-09 肺動脈高血圧の治療におけるmicroRNAの調節方法 Expired - Fee Related JP6049700B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161484091P 2011-05-09 2011-05-09
US61/484,091 2011-05-09
US201261605376P 2012-03-01 2012-03-01
US61/605,376 2012-03-01
PCT/GB2012/051018 WO2012153135A1 (en) 2011-05-09 2012-05-09 Methods of modulating micrornas in the treatment of pulmonary arterial hypertension

Publications (3)

Publication Number Publication Date
JP2014516027A JP2014516027A (ja) 2014-07-07
JP2014516027A5 true JP2014516027A5 (https=) 2015-06-11
JP6049700B2 JP6049700B2 (ja) 2016-12-21

Family

ID=46178572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014509823A Expired - Fee Related JP6049700B2 (ja) 2011-05-09 2012-05-09 肺動脈高血圧の治療におけるmicroRNAの調節方法

Country Status (11)

Country Link
US (1) US9267134B2 (https=)
EP (1) EP2707485B1 (https=)
JP (1) JP6049700B2 (https=)
KR (1) KR20140037868A (https=)
CN (1) CN103814131A (https=)
AU (1) AU2012252165A1 (https=)
BR (1) BR112013029016A2 (https=)
CA (1) CA2835568A1 (https=)
CO (1) CO6870004A2 (https=)
SG (1) SG194901A1 (https=)
WO (1) WO2012153135A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970968T3 (en) 2013-03-15 2018-03-05 Miragen Therapeutics Inc CONNECTED BICYCLIC Nucleosides
WO2014151835A1 (en) * 2013-03-15 2014-09-25 Miragen Therapeutics, Inc Locked nucleic acid inhibitor of mir-145 and uses thereof
US9840705B2 (en) * 2013-12-02 2017-12-12 The University Court Of The University Of Glasgow Materials and methods for treatment of pulmonary arterial hypertension
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CN107427698A (zh) * 2015-01-13 2017-12-01 维瓦斯公司 肺高血压的组合疗法
CA3041761A1 (en) * 2016-10-31 2018-05-03 Gifu University Double-stranded nucleic acid molecule and use thereof
CA3164050A1 (en) * 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
CN116801916A (zh) * 2021-01-18 2023-09-22 礼赞伊诺制药株式会社 包含miR 145抑制剂作为有效成分的用于治疗心肌梗塞的组合物
CN113332306A (zh) * 2021-04-28 2021-09-03 武汉华纪元生物技术开发有限公司 用于治疗肺动脉高血压的microRNA-30a抑制剂及其应用
GB202215974D0 (en) * 2022-10-28 2022-12-14 Imperial College Innovations Ltd Microrna panels for pulmonary hypertension

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
WO1995003843A1 (en) 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
GB9525620D0 (en) 1995-12-15 1996-02-14 Glaxo Group Ltd Chemical compounds
SE9600216D0 (sv) 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
CN1079396C (zh) 1996-05-31 2002-02-20 C&C新药研究所 用作选择性凝血酶抑制剂的芳族脒衍生物
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6147109A (en) 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
JP2002516256A (ja) 1998-05-26 2002-06-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 二環式糖成分を有する新規ヌクレオシド
WO2000018352A2 (en) 1998-09-28 2000-04-06 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
US20060148742A1 (en) 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
WO2005082440A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
KR101485071B1 (ko) 2005-12-12 2015-01-26 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 마이크로 rna를 이용한 근육 세포 증식 및 분화 조절방법과 근육 세포 치료방법 및 유전자 발현 억제방법그리고 마이크로 rna 분자의 발현용 벡터와 이를 이용한키트 및 미오사이트
WO2009121031A1 (en) * 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
WO2010104796A2 (en) 2009-03-09 2010-09-16 The J. David Gladstone Institutes Methods of modulating smooth muscle cell proliferation and differentiation
CN101843632B (zh) * 2009-03-24 2012-07-04 复旦大学附属华山医院 miR-145在制备治疗炎症药物中的应用
SG176716A1 (en) * 2009-06-08 2012-01-30 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
AU2010340062A1 (en) * 2009-12-15 2012-07-12 Board Of Regents, The University Of Texas System Micro-RNA regulation in ischemia and ischemia-reperfusion injury
CN102382824A (zh) 2010-09-01 2012-03-21 中国科学院上海药物研究所 人miR-145反义核酸及其应用

Similar Documents

Publication Publication Date Title
JP2014516027A5 (https=)
JP2016116520A5 (https=)
JP2012516856A5 (https=)
HRP20201200T1 (hr) OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK
MX2024005653A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
JP2017536119A5 (https=)
JP2016520310A5 (https=)
JP2016502858A5 (https=)
JP2017505623A5 (https=)
JP2013226147A5 (https=)
JP2015518712A5 (https=)
JP2014527401A5 (https=)
JP2015518710A5 (https=)
JP2015523853A5 (https=)
JP2009532392A5 (https=)
JP2015514418A5 (https=)
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
JP2012029693A5 (https=)
JP2016521556A5 (https=)
JP2012510297A5 (https=)
JP2015519057A5 (https=)
JP2015511821A5 (https=)
JP2010539959A (ja) マイクロmir
SI2929031T1 (en) PCSK9 IRNA assemblies and procedures for their use
HRP20160336T1 (hr) Protusmjerna nukleinska kiselina